Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Roche headquarters
Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Jorge Conde Andreessen Horowitz
Biotech

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Vascepa pill handout
Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Vascepa pill handout
Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Chemo Drip
Biotech

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

By Adam Feuerstein

Post society molecule landscape
Biotech

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

By Nicholas Florko

Human Melanoma Cell
Biotech

Immunotherapies targeting melanoma post encouraging results, new data show

By Adam Feuerstein

Heart graphic
Biotech

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By Adam Feuerstein

Biogen - 2015 exterior
Pharmalot

Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million

By Ed Silverman

Derek Lowe
Biotech

A medicinal chemist sees some red flags on China’s newly approved Alzheimer’s drug

By Adam Feuerstein, Rebecca Robbins, and Damian Garde

Cambridge: Sarepta
Biotech

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

By Adam Feuerstein

Brain injury
Biotech

Startup Arkuda targets rapidly advancing, rare form of dementia

By Jonathan Saltzman — Boston Globe

Howard Fillit at Milken
Biotech

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

By Nicholas Florko

Len Schleifer
Biotech

Regeneron is buying back $1 billion in stock, but hell has not yet frozen over

By Damian Garde

MORE Red Blood Cells
Biotech

ASH preview: Celgene, Bluebird, and J&J out with early but telling data in blood cancer

By Adam Feuerstein

FDA through the window
Biotech

After an unprecedented death, FDA is offered divergent forecasts on future of fecal transplants

By Kate Sheridan

Biotech

With high stakes, eight experts would wield extraordinary influence on fate of Biogen’s Alzheimer’s drug

By Damian Garde

Vascepa pill handout
Biotech

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

By Matthew Herper

Pancreatic cancer cells
Biotech

Halozyme’s lead drug fails; company will cut 55% of workforce in bid for profitability

By Matthew Herper

Fecal Transplants FDA
Biotech

FDA to consider new evidence, risks behind fecal matter transplants for C. diff treatment

By Kate Sheridan

Business

Amgen acquires stake in BeiGene to expand cancer drug business to China

By Adam Feuerstein

Social network
Biotech

Social connections first, science second: How biotech’s recipe for success has its limits

By Kate Sheridan

Cambridge: Biogen
Biotech

New MS drug from Biogen and Alkermes wins approval

By Jonathan Saltzman — Boston Globe

Novartis International pharmaceutical
Biotech

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns

By Adam Feuerstein

Lung Cancer Cells on green background
Biotech

Mirati takes a turn at the podium with a first look at its KRAS-blocking cancer drug

By Adam Feuerstein

AstraZeneca signage
Biotech

AstraZeneca aims to carve into Merck’s immunotherapy dominance

By Matthew Herper

David Hung
Biotech

Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By Kate Sheridan

Adam's Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

By Adam Feuerstein

Colon cancer cells
Biotech

Blood test maker Guardant enters race for liquid biopsy with colon cancer study

By Matthew Herper

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy